JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens. The analyses were presented by Mahmoud Ghannoum, Ph.D, Professor and Director Center for Medical Mycology, Case Western Reserve Universit
Five new “Products of the Year” were announced at the recent NutraIngredients-USA Awards spanning botanicals, immune support, omega-3s, probiotic, and sports nutrition. Read on to meet the winners…